Silence Therapeutics plc
Centre Point
103 New Oxford Street
London
WC 1A 1DD
United Kingdom
Tel: 44-0-20-73071620
Fax: 44-0-20-73071680
Website: http://www.silence-therapeutics.com/
158 articles about Silence Therapeutics plc
-
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
3/13/2024
Silence Therapeutics plc today reported its financial results for the full year ended December 31, 2023, and reviewed recent business highlights.
-
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
3/13/2024
Silence Therapeutics plc today announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 study of zerlasiran (SLN360) in 178 subjects with baseline lipoprotein(a), or Lp(a), levels at or over 125 nmol/L at high risk of atherosclerotic cardiovascular disease (ASCVD) events.
-
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
2/28/2024
Silence Therapeutics plc today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2023, on Wednesday, March 13, 2024.
-
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
2/23/2024
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”) today announced that the initiation by AstraZeneca of a phase 1 clinical trial of the first product candidate under its siRNA (short interfering RNA) collaboration, has triggered a $10.0 million milestone payment to Silence.
-
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
2/5/2024
Silence Therapeutics plc today announced an oversubscribed private placement of 5,714,286 of the Company’s American Depositary Shares (“ ADSs ”) 1 at a purchase price of US $21.00 per ADS.
-
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
1/31/2024
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference.
-
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
12/1/2023
Silence Therapeutics plc announced Curtis Rambaran, MD, previously Silence’s Vice President, Head of Clinical Science, has been promoted to Chief Medical Officer, and Marie Wikström Lindholm, PhD, previously Silence’s Senior Vice President, Head of Molecular Design, has been promoted to Chief Scientific Officer, effective immediately.
-
Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
11/14/2023
Silence Therapeutics plc reported its financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.
-
Silence Therapeutics to Present at Jefferies London Healthcare Conference - November 8, 2023
11/8/2023
Silence Therapeutics plc today announced that Craig Tooman, Silence President and CEO, will present a corporate update at the Jefferies London Healthcare Conference on Wednesday, November 15th at 4:30 p.m. GMT.
-
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
11/1/2023
Silence Therapeutics plc today announced positive topline results from the multiple dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline lipoprotein(a), or Lp(a), levels at or over 150 nmol/L and stable atherosclerotic cardiovascular disease (ASCVD).
-
Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
9/26/2023
Silence Therapeutics plc today announced the Company will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines Conference on Tuesday,
-
Silence Therapeutics to Participate in September 2023 Investor Conferences
9/6/2023
Silence Therapeutics plc announced that Company management will participate in the following investor conferences and invited investors to participate by webcast.
-
Silence Therapeutics Reports Second Quarter 2023 Results
8/16/2023
Silence Therapeutics plc today reported its financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights.
-
Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration
7/11/2023
Silence Therapeutics plc announced that it will receive a $4.0 million cash payment from Hansoh Pharmaceutical Group Company Limited following the achievement of two undisclosed preclinical milestones.
-
Silence Therapeutics to Present at the Jefferies Healthcare Conference
5/31/2023
Silence Therapeutics plc today announced that the Company will present at the Jefferies Healthcare Conference on Wednesday, June 7th at 4:00 – 4:25 PM EDT.
-
Silence Therapeutics Reports First Quarter 2023 Results
5/16/2023
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”) today reported its financial results for the first quarter ended March 31, 2023 and reviewed recent business highlights.
-
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
5/4/2023
Silence Therapeutics plc today announced that AstraZeneca has nominated the first product candidate under its siRNA (short interfering RNA) collaboration and will pay Silence a $10 million option fee to advance development on an undisclosed program.
-
Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
5/1/2023
Silence Therapeutics plc today announced that it has completed enrollment in the ALPACAR-360 phase 2 study of zerlasiran (SLN360) in subjects with elevated lipoprotein(a) (“Lp(a)”) at high risk of atherosclerotic cardiovascular disease (“ASCVD”) events.
-
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference
4/25/2023
Silence Therapeutics plc today announced that Company management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2nd at 3:30 p.m. ET.
-
Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera
4/4/2023
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”) today announced publication of human genomic and in vivo preclinical data linking iron regulation to polycythemia vera (PV) in the latest issue of Blood, the medical journal of the American Society of Hematology (ASH).